Department of Dermatology

Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution Tolerability and efficacy of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch: a multicenter, retrospective study (2022) Salzmann M, Wald A, Stege H, Loquai C, Zimmer L, Hayani K, Heinzerling L, et al. Conference contribution Which patients should receive adjuvant treatment - an analysis of stage IIA-IIIA patients of the CMMR (2022) Leiter-Stoppke U, Keim U, Amaral T, Forschner A, Berking C, Gesierich A, Gutzmer R, et al. Conference contribution The quality of national skin cancer screening from the perspective of general practitioners: A questionnaire-based comparison between Saxony and Bavaria (SaBaScreen) (2022) Strasser C, Reinhardt L, Steeb T, Wessely A, Schelling J, Petzold A, Heppt M, et al. Conference contribution SOX10-based drug repurposing identifies novel therapeutic targets in uveal melanoma (2022) Wessely A, Kammerbauer C, Lischer C, Weich A, Vera J, Berking C, Heppt M Conference contribution In vitro assessment of checkpoint-induced cytokine levels as new tool in the therapeutic decision-making process after checkpoint-induced cytokine release syndrome in metastatic melanoma (2022) Kramer R, Bender-Säbelkampf S, Berking C, Heppt M, Erdmann M, Bosch-Voskens C Conference contribution